600 new cannabinoid candidates swell Corbus pipeline

24 September 2018

Corbus Pharmaceuticals (Nasdaq: CRBP) has bought global rights to more than 600 cannabinoid-based compounds from Jenrin Discovery.

The jewel in the crown is CRB-4001, a CB1 inverse agonist targeting liver, lung, heart and kidney fibrotic diseases, which has a number of issued and pending patents.

The news sent shares in the East Coast, USA-based company soaring more than 50% on Thursday, before falling nearly 15% in the following day’s trade, likely a result of some investors cashing in on the sudden spike.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK